Nordic Nanovector in collaboration with AREVA Med on leukemia treatments

1 July 2016

Norwegian biotech company Nordic Nanovector has joined forces with US company AREVA Med to investigate the potential of lead-212 conjugated anti-CD37 antibody for treating leukemias, it has been announced.

Under the terms of the agreement, Nordic Nanovector will provide its chimeric anti-CD37 antibody (NNV003) and its expertise in antibody radionuclide conjugate (ARC) development, while AREVA Med will provide expertise in the production of 212pb.

Nordic Nanovector’s chief scientific officer, Jostein Dahle, said: “The CD37 antigen is expressed on the surface of many hematological cancer cells, including leukemia cells, making it an important target for ARC-based therapies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK